Conmed Stock News

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Endoscopy Equipment Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow. Northbrook, IL -- ( SBWIRE ) -- 02/24/2022 -- This report aims to provide detailed insights into the global endoscopy equipment market . It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market. Expected Revenue Growth: The global endoscopy equipment market is projected to reach USD 39.3 billion by 2026 from USD 27.3 billion in 2021, at a CAGR of 7.5%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689 Key Factors Driving Market Growth: The key factors driving the growth of endoscopy equipment market include favorable government initiatives, rising number of hospitals and growing hospital investments in endoscopy facilities, technological advancements, and rising prevalence of diseases that require endoscopy.

HSIC vs. CNMD: Which Stock Is the Better Value Option?

CONMED Corporation (NYSE: CNMD ) reported Q4 FY21 adjusted EPS of $1.07 , compared to $0.84 a year ago, and better than the consensus of $1.06. Sales for the quarter rose 8.4% Y/Y to $273.97 million, missing the consensus of $278.76 … Full story available on Benzinga.com

CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.

CONMED Corporation (CNMD) CEO Curt Hartman On Q4 2021 Results - Earnings Call Transcript

We think that Stryker Corporation currently is a better bet compared to Conmed Corp. CNMD stock trades at 4x trailing revenues, lower than that of SYK, whose P/S multiple stands at 6.1x. Does this gap

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed

PDCO vs. CNMD: Which Stock Is the Better Value Option?

CONMED (NYSE:CNMD) and ViewRay (NASDAQ:VRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Earnings and Valuation This table compares CONMED and ViewRays top-line revenue, earnings per share and valuation. Gross Revenue [] The post Contrasting CONMED (NYSE:CNMD) and ViewRay (NASDAQ:VRAY) appeared first on ETF Daily News .

Los Angeles, United State, ,- This research study is one of the most detailed and accurate ones that solely focus on the global Gastrointestinal Bleeding Treatment market. It sheds light on critical factors that impact the growth of the global

PDCO vs. CNMD: Which Stock Is the Better Value Option?

New Jersey, United States,- Verified Market Research has recently published a research report titled, Myomectomy Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to formulate this

CONMED Co. (NYSE:CNMD) declared a quarterly dividend on Monday, November 29th, RTT News reports. Stockholders of record on Wednesday, December 15th will be given a dividend of 0.20 per share on Wednesday, January 5th. This represents a $0.80 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, December […]